201 related articles for article (PubMed ID: 26775096)
1. Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
Brieau B; Auzolle C; Pozet A; Tougeron D; Bouché O; Soibinet P; Coriat R; Prieux C; Lecomte T; Goujon G; Marthey L; Rougier P; Bonnetain F; Ducreux M; Taieb J; Zaanan A
Dig Liver Dis; 2016 Apr; 48(4):441-5. PubMed ID: 26775096
[TBL] [Abstract][Full Text] [Related]
2. Chemosensitivity in ovarian metastases from gastric cancer: a case series.
Brieau B; Roussel H; Markoutsaki T; Dubreuil O; Trouilloud I; Landi B; Lepère C; Vaillant JN; Berger A; Rougier P; Taieb J; Zaanan A
Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):289-95. PubMed ID: 23142590
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
4. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.
Erdem GU; Bozkaya Y; Ozdemir NY; Demirci NS; Yazici O; Zengin N
Bosn J Basic Med Sci; 2018 May; 18(2):170-177. PubMed ID: 28941466
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy.
Geng R; Chen Z; Zhao X; Qiu L; Liu X; Liu R; Guo W; He G; Li J; Zhu X
PLoS One; 2014; 9(12):e116027. PubMed ID: 25545243
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey.
Teker F; Yilmaz B; Kemal Y; Kut E; Yucel I
Asian Pac J Cancer Prev; 2014; 15(16):6727-32. PubMed ID: 25169516
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
Kaya AO; Coskun U; Gumus M; Dane F; Ozkan M; Isıkdogan A; Alkis N; Buyukberber S; Yumuk F; Budakoglu B; Demirci U; Berk V; Bilici A; Inal A; Arpacı E; Benekli M;
J Chemother; 2012 Aug; 24(4):217-20. PubMed ID: 23040686
[TBL] [Abstract][Full Text] [Related]
9. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.
Turkmen E; Erdogan B; Kodaz H; Hacibekiroglu I; Onal Y; Uzunoglu S; Kilic N; Cicin I
Acta Gastroenterol Belg; 2016; 79(2):211-5. PubMed ID: 27382940
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for ovarian metastases from primary gastric cancer.
Wang J; Shi YK; Wu LY; Wang JW; Yang S; Yang JL; Zhang HZ; Liu SM
Int J Gynecol Cancer; 2008; 18(4):825-32. PubMed ID: 17892453
[TBL] [Abstract][Full Text] [Related]
11. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
12. A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study.
Choi IS; Kim JH; Lee JH; Suh KJ; Lee JY; Kim JW; Kim SH; Kim JW; Lee JO; Kim YJ; Bang SM; Lee JS; Lee KW
PLoS One; 2018; 13(10):e0205853. PubMed ID: 30346970
[TBL] [Abstract][Full Text] [Related]
13. Palliative chemotherapy for advanced gastric cancer.
Wöhrer SS; Raderer M; Hejna M
Ann Oncol; 2004 Nov; 15(11):1585-95. PubMed ID: 15520058
[TBL] [Abstract][Full Text] [Related]
14. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.
Kang JH; Lee SI; Lim DH; Park KW; Oh SY; Kwon HC; Hwang IG; Lee SC; Nam E; Shin DB; Lee J; Park JO; Park YS; Lim HY; Kang WK; Park SH
J Clin Oncol; 2012 May; 30(13):1513-8. PubMed ID: 22412140
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.
Seo MD; Lee KW; Lim JH; Yi HG; Kim DY; Oh DY; Kim JH; Im SA; Kim TY; Lee JS; Bang YJ
Jpn J Clin Oncol; 2008 Sep; 38(9):589-95. PubMed ID: 18772169
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological study of gastric cancer with ovarian metastasis.
Kobayashi O; Sugiyama Y; Cho H; Tsuburaya A; Sairenji M; Motohashi H; Yoshikawa T
Int J Clin Oncol; 2003 Apr; 8(2):67-71. PubMed ID: 12720097
[TBL] [Abstract][Full Text] [Related]
17. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
[TBL] [Abstract][Full Text] [Related]
18. [Oophorectomy for Ovarian Metastasis Occurring during Chemotherapy in Gastric Cancer Patients with Peritoneal Dissemination--Report of Three Cases].
Ichihara M; Fujiwara Y; Omori T; Miyoshi N; Sugimura K; Akita H; Motoori M; Gotoh K; Takahashi H; Kobayashi S; Noura S; Miyata H; Ohue M; Sakon M; Yano M
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1527-9. PubMed ID: 26805085
[TBL] [Abstract][Full Text] [Related]
19. Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil.
Shimada S; Yagi Y; Kuramoto M; Aoki N; Ogawa M
Oncol Rep; 2003; 10(3):687-91. PubMed ID: 12684644
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Seo S; Park SJ; Ryu MH; Park SR; Ryoo BY; Park YS; Na YS; Lee CW; Lee JK; Kang YK
Oncotarget; 2017 May; 8(20):33844-33854. PubMed ID: 27802183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]